Earnings ·
Moleculin Biotech reported second quarter 2026 financial results and highlighted positive interim data from its…
MBRXMoleculin Biotech, Inc.
Moleculin Biotech reported second quarter 2026 financial results and highlighted positive interim data from its pivotal MIRACLE trial for Annamycin in relapsed or refractory acute myeloid leukemia. Complete remission rates were at least three times higher than the control arm, with 43% and 36% observed in the two treatment cohorts versus 12% for control. The company raised $9.3 million in financing proceeds after the quarter end, bringing total cash resources to approximately $16.6 million alongside existing balances, which is expected to fund operations into the first quarter of 2027. R&D expenses increased to $5.5 million from $3.6 million in the prior year period due to clinical trial costs. The company operates as a clinical-stage pharmaceutical developer focused on oncology therapies.